Summary

173.53 -0.34(-0.19%)07/26/2024
PTC Inc (PTC)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 YearsAll Time
-0.25-1.36-2.30-4.12-3.9220.35136.559,419.50


Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1


Trading Data
Close173.53
Open174.95
High176.77
Low173.50
Volume602,052
Change-0.43
Change %-0.25
Avg Volume (20 Days)805,851
Volume/Avg Volume (20 Days) Ratio0.75
52 Week Range134.61 - 194.18
Price vs 52 Week High-10.63%
Price vs 52 Week Low28.92%
Range-0.81
Gap Up/Down-1.04
Fundamentals
Market Capitalization (Mln)20,812
EBIDTA607,523,968
PE Ratio75.3138
PEG Ratio1.8485
WallStreet Target Price203.24
Book Value24.5840
Earnings Per Share2.3900
EPS Estimate Current Quarter1.2300
EPS Estimate Next Quarter1.2100
EPS Estimate Current Year4.9200
EPS Estimate Next Year5.8100
Diluted EPS (TTM)2.3900
Revenues
Profit Marging0.1284
Operating Marging (TTM)0.2982
Return on asset (TTM)0.0533
Return on equity (TTM)0.1054
Revenue TTM2,242,247,936
Revenue per share TTM18.8420
Quarterly Revenue Growth (YOY)0.1120
Quarterly Earnings Growth (YOY)0.7920
Gross Profit (TTM)1,656,047,000
Dividends
Dividend Share0.0000
Dividend Yield
Valuations
Trailing PE75.3138
Forward PE38.0228
Price Sales (TTM)0.0000
Price Book (MRQ)7.6698
Revenue Enterprise Value 10.8705
EBITDA Enterprise Value38.0703
Shares
Shares Outstanding119,744,000
Shares Float112,365,619
Shares Short0
Shares Short (Prior Month)0
Shares Ratio0.00
Short Outstanding (%)0.00
Short Float (%)0.02
Insider (%)6.10
Institutions (%)97.60


07/26 10:30 EST - globenewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.
07/25 16:30 EST - prnewswire.com
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, Aug. 8, at 4:30 p.m.
07/24 11:06 EST - zacks.com
PTC Inc. (PTC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
PTC Inc. (PTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/19 13:16 EST - zacks.com
Why PTC Inc. (PTC) Could Beat Earnings Estimates Again
PTC Inc. (PTC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
07/12 15:20 EST - globenewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.
07/12 15:02 EST - seekingalpha.com
PTC: A Bullish Bet With ServiceMax Integration Boost
PTC Inc. provides lifecycle management software and services globally. The global PLM market is expected to grow at a CAGR of 8.6% from 2022 to 2030, with PTC competing with major industry players. PTC has shown revenue and earnings growth, and strong free cash flow.
07/11 08:00 EST - prnewswire.com
PTC to Announce Fiscal Q3'24 Results on Wednesday, July 31st, 2024
BOSTON , July 11, 2024 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2024 third quarter results on Wednesday, July 31 st after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, July 31 st at 5pm Eastern Time.
07/10 10:00 EST - accesswire.com
Bronstein, Gewirtz and Grossman, LLC sends a Class Action Lawsuit reminder to shareholder investors for PTC Therapeutics, Inc to Lead the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
07/03 09:20 EST - zacks.com
PTC Stock Surges 30% in a Year: Will the Momentum Continue?
PTC's performance gains from solid momentum across the PLM and CAD business segments.
06/28 09:30 EST - investorplace.com
3 Robotics Stocks That Could Make Your Grandchildren Rich
The best robotics stocks to buy are those that will continue to attract investors who are trying to future-proof their portfolios. That's because the market could to grow 15.91% from $45.85 billion in 2024 to $95.93 billion in 2029.
06/27 06:51 EST - fool.com
1 Long-Term Growth Stock to Buy Hand Over Fist and 1 to Avoid
Automation is the future of manufacturing, and this company has a bright future, but its management needs to restore confidence in its guidance. This industrial software provider is about to start generating some serious cash flow.